Gilead Sciences, Inc. (GILD) |
65.42 0.15 (0.23%) 04-26 16:00 |
Open: | 65.5 |
High: | 66.3507 |
Low: | 64.64 |
Volume: | 12,348,617 |
Market Cap: | 81,577(M) |
PE Ratio: | 14.54 |
Exchange: | NASDAQ Global Select |
Industry: | Drug Manufacturers - General |
Sector: | Healthcare |
Technical analysis | ||||
sell | buy |
Resistance 2: | 73.87 |
Resistance 1: | 70.34 |
Pivot price: | 67.39 |
Support 1: | 64.64 |
Support 2: | 53.78 |
52w High: | 87.87 |
52w Low: | 64.63 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
EPS | 4.500 |
Book Value | 18.330 |
PEG Ratio | 2.46 |
Gross Profit | 0.000 |
Profit Margin (%) | 20.89 |
Operating Margin (%) | 42.21 |
Return on Assets (ttm) | 9.8 |
Return on Equity (ttm) | 25.5 |
Fri, 26 Apr 2024
Gilead Sciences Inc. stock rises Friday, still underperforms market - MarketWatch
Fri, 26 Apr 2024
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat - Zacks Investment Research
Fri, 26 Apr 2024
Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat - Yahoo Finance
Thu, 25 Apr 2024
Gilead has strong Q1, but updated 2024 EPS guidance range misses consensus - Seeking Alpha
Thu, 25 Apr 2024
Gilead (GILD) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance
Thu, 25 Apr 2024
Gilead Beats Earnings Expectations After Rocky Quarter - Barron's
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |